Arvind Agrawal
CFO, Ajanta Pharma
Notable Quotes
We remain confident of maintaining EBITDA margin of 27% with a variation of ±1% in the coming year as well, while making further investment in developing our market.
We expect the EBITDA to be around this range, plus/minus 1%, for whole of FY 2025.
We expect the EBITDA to be around this range, ±1%, for whole of 2025.
If the position improves or some changes happen, we should be able to deliver 28% EBITDA. If we get some tailwinds, 100 basis point improvement should be possible.
We are revising our full year guidance to 27% ±1% for full year financial year 2024.
We retain our guidance of about 25% ±1% EBITDA margin for FY 2024.